Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Vistra Corp (VST) Price & Performance

Medpace Holdings IncTrade
Vistra CorpTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Vistra Corp — how do they compare? Medpace Holdings Inc trades at $616.83 (market cap $16.82B), while Vistra Corp trades at $159.93 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 3.1× Medpace Holdings Inc's market cap, and Vistra Corp pays a 0.59% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vistra Corp for 32 Days on average.

MEDPVST
Market Cap
$16.82B$52.41B
Volume
223,09311,278,074
Sector
HealthUtilities
52-Week High
$630.19$210.85
52-Week Low
$393.42$134.71
Typical Hold Time
14 Days32 Days
Enterprise Value
$16.44B$74.34B
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.

Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.

Vistra Corp

Vistra Corp (VST) trades at $156.19, down 6.32% today, but maintains strong analyst support with 91% buy ratings and a $215.23 consensus target. The stock shows bullish technical signals with support at $152 and resistance at $164, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.

Vistra presents compelling growth potential as a key beneficiary of AI infrastructure expansion, with strong profitability metrics and institutional backing. However, investors face risks from volatile earnings performance (two recent EPS misses) and execution challenges in capital-intensive energy projects. The stock's current discount to analyst targets offers upside potential if the company can consistently deliver on its nuclear expansion and data center power contracts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MEDP
100% Buy0% Sell
Avg holding period · 14 Days
VST
21% Buy79% Sell
Avg holding period · 32 Days

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP →

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.

Read more on VST →